Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study

被引：1
|
作者：
Chen, X. [1 ]
Zhang, S. [1 ]
Li, X. [2 ]
Zhang, Y. [1 ]
Li, Y. [2 ]
Kang, H. [1 ]
Guan, H. [1 ]
She, Q. [2 ]
Ma, X. B. [1 ]
Diao, Y. [1 ]
Liu, D. [1 ]
Min, W. [1 ]
Liu, M. [1 ]
Wu, F. [1 ]
Feng, C. [1 ]
机构：
[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Oncol, Xian, Peoples R China
[2] Baoji Cent Hosp, Oncol, Baoji, Shaanxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169P
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
    Bruges Maya, R.
    Urrego, J. C.
    Marrugo, C.
    Wurcel, V.
    Khandelwal, A.
    Singh, J.
    Huang, M.
    Haiderali, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S286 - S286
  • [22] Safety and ef fi cacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial
    Liang, Yan
    Liu, Jing
    Ge, Jia
    Shi, Qiyun
    Zhang, Guozhi
    Wan, Andi
    Luo, Tao
    Tian, Hao
    Fan, Linjun
    Wang, Shushu
    Chen, Li
    Tang, Peng
    Zhu, Kai
    Jiang, Jun
    Bian, Xiuwu
    Zhang, Yi
    Qi, Xiaowei
    ECLINICALMEDICINE, 2024, 71
  • [23] Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
    Bagegni, Nusayba A.
    Davis, Andrew A.
    Clifton, Katherine K.
    Ademuyiwa, Foluso O.
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 113 - 123
  • [24] Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02)
    Chen, Peng-Ju
    Wang, Lin
    Sun, Ting-Ting
    Yao, Yun-Feng
    Peng, Yi-Fan
    Zhao, Jun
    Zhan, Tian-Cheng
    Leng, Jia-Hua
    Cai, Yong
    Li, Yong-Heng
    Zhang, Xiao-Yan
    Sun, Ying-Shi
    Li, Zhong-Wu
    Wang, Wei-Hu
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [25] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
    Li, H.
    Zhou, D.
    Yv, Z.
    Liao, Y.
    Huang, J.
    Sun, S.
    Zheng, F.
    Li, B.
    Fang, S.
    Qiang, L.
    Ren, G.
    Wang, X.
    Zhang, B.
    Fan, B.
    Zhao, X.
    Li, W.
    Wang, Z.
    Fu, H.
    Sun, X.
    Shi, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S368 - S368
  • [26] Anlotinib plus chemoradiotherapy in the treatment for FIGO stage IB3 and IIB-IVA cervical cancer: A prospective single-arm, single-center, exploratory phase II trial
    Secord, Angeles Alvarez
    Barroilhet, Lisa
    Gupta, Sunil
    Oosman, Sonia
    Tewari, Devansu
    Barlin, Joyce
    Provencher, Diane
    Gold, Michael
    Breed, Christopher
    Edraki, Babak
    Brooks, Rebecca
    Modesitt, Susan
    Braly, Patrica
    Jada, Srinivasa
    Schorge, John
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S157 - S157
  • [27] Neoadjuvant Toripalimab plus chemotherapy in patients with stage IIB-IIIB NSCLC: A single-center, prospective, single-arm, phase 2 trial (Renaissance Study).
    Yan, Shi
    Chen, Jinfeng
    Wang, Jia
    Lv, Chao
    Bi, Jiwang
    Yang, Xin
    Li, Shaolei
    Wang, Yuzhao
    Li, Xiang
    Yang, Yue
    Wu, Nan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Phase II study of camrelizumab plus chemotherapy as neoadjuvant therapy in patients with early triple-negative breast cancer
    Wang, Y.
    Liu, Y.
    Zhu, S.
    Bi, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S616 - S616
  • [29] FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer
    Shah, Mirat
    Osgood, Christy L.
    Amatya, Anup K.
    Fiero, Mallorie H.
    Pierce, William F.
    Nair, Abhilasha
    Herz, Jonathan
    Robertson, Kim J.
    Mixter, Bronwyn D.
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5249 - 5253
  • [30] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Favre-Bulle, Andrea
    Huang, Min
    Haiderali, Amin
    Bhadhuri, Arjun
    PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 91 - 101
12345